Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Mesenchymal stem cell therapy in perinatal arterial ischemic stroke : systematic review of preclinical studies

Lehnerer, Verena ; Roidl, Anna ; Romantsik, Olga LU ; Guzman, Raphael ; Wellmann, Sven and Bruschettini, Matteo LU orcid (2024) In Pediatric Research 95(1). p.18-33
Abstract

Background: Perinatal arterial ischemic stroke (PAIS) is a neurologic disorder leading to long-term complications. Mesenchymal stem cells (MSCs) have emerged as a novel therapeutic agent. This systematic review aims to determine the effects of stem cell-based interventions for the treatment of PAIS in preclinical studies. Methods: We included all controlled studies on MSCs in neonatal animals with PAIS. Functional outcome was the primary outcome. The literature search was performed in February 2021. Results: In the 20 included studies, MSCs were most frequently delivered via intracerebral injection (n = 9), 3 days after the induction of PAIS (n = 8), at a dose ranging from 5 × 104 to 5 × 106 cells. The... (More)

Background: Perinatal arterial ischemic stroke (PAIS) is a neurologic disorder leading to long-term complications. Mesenchymal stem cells (MSCs) have emerged as a novel therapeutic agent. This systematic review aims to determine the effects of stem cell-based interventions for the treatment of PAIS in preclinical studies. Methods: We included all controlled studies on MSCs in neonatal animals with PAIS. Functional outcome was the primary outcome. The literature search was performed in February 2021. Results: In the 20 included studies, MSCs were most frequently delivered via intracerebral injection (n = 9), 3 days after the induction of PAIS (n = 8), at a dose ranging from 5 × 104 to 5 × 106 cells. The meta-analysis showed an improvement on the cylinder rearing test (MD: −10.62; 95% CI: −14.38 to −6.86) and on the water maze test (MD: 1.31 MD; 95% CI: 0.80 to 1.81) in animals treated with MSCs compared to the control group animals. Conclusion: MSCs appear to improve sensorimotor and cognitive performance in PAIS-injured animals; however, the certainty of the evidence is low. Registration of the protocol of preclinical studies, appropriate sample size calculation, rigorous randomization, and reporting of the data on animal sex and survival are warranted. PROSPERO registration number: CRD42021239642. Impact: This is the first systematic review and meta-analysis of preclinical studies investigating the effects of MSCs in an experimental model of PAIS.MSCs appear to improve sensorimotor and cognitive performance in PAIS-injured neonatal animals.The certainty of the evidence is low due to high or unclear risk of bias in most domains.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pediatric Research
volume
95
issue
1
pages
16 pages
publisher
International Pediatric Foundation Inc.
external identifiers
  • pmid:35906311
  • scopus:85144017096
ISSN
0031-3998
DOI
10.1038/s41390-022-02208-3
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2022, The Author(s).
id
9eeb7ed1-7150-4b69-8b27-0ef057a2345a
date added to LUP
2026-07-02 15:03:02
date last changed
2026-09-24 21:47:47
@article{9eeb7ed1-7150-4b69-8b27-0ef057a2345a,
  abstract     = {{<p>Background: Perinatal arterial ischemic stroke (PAIS) is a neurologic disorder leading to long-term complications. Mesenchymal stem cells (MSCs) have emerged as a novel therapeutic agent. This systematic review aims to determine the effects of stem cell-based interventions for the treatment of PAIS in preclinical studies. Methods: We included all controlled studies on MSCs in neonatal animals with PAIS. Functional outcome was the primary outcome. The literature search was performed in February 2021. Results: In the 20 included studies, MSCs were most frequently delivered via intracerebral injection (n = 9), 3 days after the induction of PAIS (n = 8), at a dose ranging from 5 × 10<sup>4</sup> to 5 × 10<sup>6</sup> cells. The meta-analysis showed an improvement on the cylinder rearing test (MD: −10.62; 95% CI: −14.38 to −6.86) and on the water maze test (MD: 1.31 MD; 95% CI: 0.80 to 1.81) in animals treated with MSCs compared to the control group animals. Conclusion: MSCs appear to improve sensorimotor and cognitive performance in PAIS-injured animals; however, the certainty of the evidence is low. Registration of the protocol of preclinical studies, appropriate sample size calculation, rigorous randomization, and reporting of the data on animal sex and survival are warranted. PROSPERO registration number: CRD42021239642. Impact: This is the first systematic review and meta-analysis of preclinical studies investigating the effects of MSCs in an experimental model of PAIS.MSCs appear to improve sensorimotor and cognitive performance in PAIS-injured neonatal animals.The certainty of the evidence is low due to high or unclear risk of bias in most domains.</p>}},
  author       = {{Lehnerer, Verena and Roidl, Anna and Romantsik, Olga and Guzman, Raphael and Wellmann, Sven and Bruschettini, Matteo}},
  issn         = {{0031-3998}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{18--33}},
  publisher    = {{International Pediatric Foundation Inc.}},
  series       = {{Pediatric Research}},
  title        = {{Mesenchymal stem cell therapy in perinatal arterial ischemic stroke : systematic review of preclinical studies}},
  url          = {{http://dx.doi.org/10.1038/s41390-022-02208-3}},
  doi          = {{10.1038/s41390-022-02208-3}},
  volume       = {{95}},
  year         = {{2024}},
}